Umida Group AB (”Umida”, ”Koncernen” eller ”Bolaget”) meddelade den 7 april år 2025 att Bolaget har ...
Medtech is not exempt from US reciprocal tariffs, unlike Pharma.
Redeye leaves a comment on Curasight following Friday's announcement of a DKK100m rights issue.
On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for rei...
Incorporating Doro lifts '26e-'27e EBITA by 25-53% We forecast a '25e-'28e EBITA CAGR of 32%.
Report due 6 May 2025 Q1e net sales of SEK 209m, EBITA of SEK 34m We reiterate our fair value range ...
Redeye is pleased to note that Smart Eye announced two new design wins worth SEK200m today with an u...
Redeye comments on NextCell Pharma ahead of the upcoming interim data from ProTrans-Young, set to be...
Redeye gives a short comment on the positive preliminary outcome of Saniona’s TO4 warrant program.
Redeye comments on the intriguing news that a newly published article in Nature highlights the poten...
Nosa Plugs AB (“Nosa Plugs” or “the Company”) announced on April 2, 2025, that it has reached its ta...
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK35.
Q1e: Flat organic sales growth, 5.3% adj. EBITA margin Expect Sweden to weigh on growth, awaiting AD...
NoHo Partners is separating its subgroup Better Burger Society from the group, while retaining a maj...
Redeye updates its view on Flexion Mobile following its Q4 2024 report, which was softer than expect...
